NASDAQ · UXIN

Uxin Limited

$1.50 -$0.02 (-1.32%) 1D Market open

Key Metrics

$334.37M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow −$75.19M
Beta · 1Y 1.35
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 2
    The stock moved -16.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 2
  • Jul 1
    The stock moved +25.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 1
  • Jun 29
    From its Mar 17 high, the share price fell 60%.

    Peak close $3.78 on Mar 17; trough close $1.50 on Jun 29. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -60%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$334.37M
Enterprise value$376.40M
Shares outstanding220.0M
52-wk range$1.42 – $4.50
Avg volume · 20D162.4K
Net cash −$42.03M
Book value / share$-0.15
ExchangeNASDAQ
About Uxin Limited
IPO dateJun 27, 2018
Employees2437

Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio0.76
Quick ratio0.20
Debt / equity-1.63
Debt / EBITDA
Net cash −$42.03M
Working capital−$33.32M

Cash Flow · TTM

Operating CF −$72.12M
Capex −$3.07M
Free cash flow −$75.19M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings